Used in the treatment of inflammatory and autoimmune diseases, particularly targeting conditions where GM-CSF (granulocyte-macrophage colony-stimulating factor) plays a key role in driving inflammation. This antibody neutralizes GM-CSF activity, making it a therapeutic candidate for rheumatoid arthritis, multiple sclerosis, and other chronic inflammatory disorders. It has also been investigated for its potential in reducing lung inflammation in diseases such as COPD and pulmonary alveolar proteinosis. Due to its high specificity and neutralizing capacity, it serves as a reference in developing biosimilars and evaluating anti-GM-CSF therapeutics in preclinical and clinical research.